<DOC>
	<DOCNO>NCT01891643</DOCNO>
	<brief_summary>The purpose study look subject receive Lenalidomide , Dexamethasone , Elotuzumab determine low surface CS1 expression malignant plasma cell time progression receive Lenalidomide Dexamethasone without Elotuzumab</brief_summary>
	<brief_title>PH III Study Lenalidomide Dexamethasone With Without Elotuzumab Treat Previously Untreated Multiple Myeloma ( ELO 1 Substudy )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Subjects newly diagnose symptomatic MM : Have receive prior systemic antimyeloma therapy Have measurable disease And candidate highdose therapy plus stemcell transplantation ( SCT ) age ( â‰¥65 year ) coexist condition . Refusal undergo high dose therapy SCT NOT sufficient entry onto CA204006 subject &lt; 65 year old . There must comorbidity prevents SCT subject &lt; 65 year old Subjects nonsecretory oligosecretory free lightchain myeloma Smoldering MM , define asymptomatic MM absence lytic bone lesion Monoclonal Gammopathy Undetermined Significance ( MGUS ) Active plasma cell leukemia Known Human Immunodeficiency Virus ( HIV ) infection active hepatitis A , B , C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>